Treatment options and treatments for neurodegenerative disorders
By administering sigma receptor agonists and analyzing gene expression changes, the method addresses the inadequacies of current genomic profiling for treatment selection in neurodegenerative disorders, enabling personalized and effective treatment strategies.
Patent Information
- Application Number
- JP2024530556
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-07-29
- Filing Date
- 2022-11-23
- Publication Date
- 2024-11-15
AI Technical Summary
Current genomic profiling methods are inadequate for assessing the effectiveness of treatments or selecting appropriate therapeutic agents for patients, particularly in neurodegenerative disorders such as Alzheimer's and Parkinson's disease.
A method involving the administration of sigma receptor agonists like ANAVEX2-73 to patients, followed by gene expression profiling before and after treatment, to identify differentially expressed genes and gene clusters, enabling personalized treatment selection and monitoring.
This approach allows for the identification of effective therapeutic agents and evaluation of neurodegenerative treatments by analyzing gene expression changes, thereby personalizing treatment strategies and improving patient outcomes.
Smart Images

Figure 2024542523000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 282,615, filed November 23, 2021, and U.S. Provisional Patent Application No. 63 / 393,573, filed July 29, 2022, both of which are incorporated by reference in their entireties.
[0002] The present disclosure relates generally to personalized medical treatments, and more specifically to genetic methods and kits for personalized monitoring of medical treatments and selection of therapeutic agents. [Background technology]
[0003] Genomics is an interdisciplinary field of biology that focuses on the structure, function, evolution, mapping, and editing of genomes. Over the past few decades, genome analysis and profiling have become useful tools for diagnosing, treating, and preventing diseases. However, there are few reports on how to use genome profiling to evaluate the effectiveness of treatments or to select appropriate therapeutic agents for specific patients. Summary of the Invention [Means for solving the problem]
[0004] Certain aspects of the present disclosure include methods of selecting a therapeutic agent for a subject suffering from a disease or disorder selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction.The method includes obtaining or obtaining a first biological sample from a subject, administering a sigma receptor agonist to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify at least one differentially expressed gene and / or overrepresented gene. and identifying a differentially expressed gene cluster comprising: (i) at least one of the differentially expressed genes is a gene listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or is a gene listed in a second gene cluster comprising COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDU FA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, U If any one of the following is observed: (i) the identified over-represented gene cluster is a gene listed in the second gene cluster, including QCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) the identified over-represented gene cluster overlaps with the genes listed in the first gene cluster or the genes listed in the second gene cluster, select a sigma receptor agonist as a therapeutic agent for the subject. In either method, the therapeutic agent can include a sigma receptor agonist.Sigma receptor agonists may include ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts, or any combination thereof. In any method, the therapeutic agent may comprise a sigma receptor agonist selected from ANAVEX2-73 (A2-73), A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-)A2-73 enantiomer, or the (+)A2-73 enantiomer, or a combination thereof.
[0005] In the present methods, the therapeutic agent can be administered for a period of up to 14 weeks, such as about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks. Also, the therapeutic agent is administered daily, such as, for example, once a day.
[0006] In various other aspects of the method, the sigma receptor agonist may include A2-73, A2-73 free base, or any combination thereof. In another aspect of the method, the sigma receptor agonist may include a crystalline form of A2-73, administered in an amount of about 40 mg to about 60 mg once a day for about 6 weeks to about 11 weeks. For example, the crystalline form of A2-73 is administered in a dose of about 50 mg per day for up to 11 weeks. Alternatively, A2-73 is administered once a day daily for a period of 6 weeks to 11 weeks in escalating doses starting at about 10 mg and ending at about 50 mg. In another aspect, the sigma receptor agonist includes A2-73, A2-73 free base, or any combination thereof. In some aspects, A2-73 or A2-73 free base is administered daily in an amount of about 40 mg to about 60 mg for a period of 6 weeks to 14 weeks. In yet another embodiment, the sigma receptor agonist comprises a crystalline form of A2-73 or A2-73 free base, and the A2-73 or A2-73 free base is administered once daily in an amount of about 50 mg for a period of up to 11 weeks. In yet another embodiment, the therapeutic agent is a sigma receptor agonist, and the sigma receptor agonist comprises a crystalline form of A2-73. The A2-73 crystals are administered once daily in escalating doses starting at about 10 mg and ending at about 50 mg for a period of 11 weeks.
[0007] Another aspect of the present disclosure includes a method of assessing the effectiveness of a neurodegenerative therapy in a subject in need thereof.The method includes obtaining or obtaining a first biological sample from a subject, administering a neurodegenerative therapy to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the treatment period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters. determining whether or not the differentially expressed genes are genes listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; or (ii) determining whether or not the differentially expressed genes are genes listed in a first gene cluster comprising COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A , NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ , NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (iii) the identified overrepresented gene cluster overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster; and identifying the neurodegenerative treatment as ineffective for the subject if any of the above conditions are not met.
[0008] In another aspect of the method, if a neurodegenerative therapy is identified as ineffective in a subject, follow-up measures may include switching to an alternative neurodegenerative therapy, supplementing with an alternative neurodegenerative therapy, adjusting the dosage if the neurodegenerative therapy is a drug therapy, or switching to a combination neurodegenerative therapy.
[0009] In any of the methods, the subject may be a human subject having or suspected of having a neurodegenerative disease, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, a prion disease, or any combination thereof.
[0010] In any of the methods, the neurodegenerative therapy can be a medication including ANAVEX2-73 (A2-73), ANAVEX 19-144, ANAVEX1-41, AV1066, ANAVEX3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts. For example, the neurodegenerative therapy is an A2-73 medication including A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-)A2-73 enantiomer, or (+)A2-73 enantiomer.
[0011] In yet another embodiment, the neurodegenerative therapy may be administered for a period of up to 14 weeks, such as about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks. The therapeutic agent may be administered daily, such as once daily or twice daily.
[0012] In yet another embodiment of the method, the neurodegenerative treatment is a drug therapy including, for example, a crystalline form of A2-73, administered in an amount of about 40 mg to about 60 mg once a day for about 6 weeks to about 11 weeks. For example, A2-73 is administered at about 50 mg per day for up to 11 weeks. Alternatively, A2-73 is administered daily at escalating doses starting at about 10 mg and ending at about 50 mg once a day for a period of 6 weeks to 11 weeks.
[0013] Yet another aspect of the disclosure includes a method of identifying a subject responsive to sigma-1 receptor agonist therapy, comprising obtaining or obtaining a first biological sample from a subject, administering a sigma receptor agonist to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed and overrepresented genes. and identifying a differentially expressed gene cluster comprising: (i) a first gene cluster including COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; or (ii) a first gene cluster including COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; DUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, ND UFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, N or (ii) the identified overrepresented gene cluster overlaps with the genes listed in the first gene cluster or the genes listed in the second gene cluster.
[0014] In any of the methods, the subject being administered sigma-1 receptor agonist therapy is a human subject having or suspected of having a disorder or disease such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a retrograde endocannabinoid signaling associated disorder, or a disorder associated with myocardial contraction.
[0015] In various aspects of the method, the sigma-1 receptor agonist therapy can include ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts. For example, the sigma-1 receptor agonist therapy is an A2-73 medication that includes A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, or the (+) A2-73 enantiomer.
[0016] In various aspects of the method, the sigma-1 receptor agonist therapy can be administered for a period of up to 14 weeks, such as about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks, and the therapeutic agent is administered daily, such as, for example, once a day.
[0017] In various aspects of the method, the sigma-1 receptor agonist therapy may include a crystalline form of A2-73 or A2-73 free base, administered in an amount of about 40 mg to about 60 mg once a day for a period of about 6 weeks to about 11 weeks. For example, A2-73 crystals or A2-73 free base crystals are administered at about 50 mg / day for up to 11 weeks. Alternatively, A2-73 or A2-73 free base is administered daily at escalating doses starting at about 10 mg and ending at about 50 mg once a day for 6 weeks to about 11 weeks.
[0018] Another aspect of the present disclosure includes a method of determining whether a subject has or is suspected of having a disease or disorder selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, or a disorder associated with myocardial contraction, or a method of assessing a subject's risk of developing such a disease or disorder.The method includes obtaining or obtaining a first biological sample from a subject, administering a composition of ANAVEX 2-73 to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented genes. d) identifying a gene cluster, and providing: (i) the identified differentially expressed genes are genes listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1 , COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, ND UFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ (ii) the identified overrepresented gene cluster overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster. In various aspects of the method, the disease is Parkinson's disease or a prion disease.The A2-73 composition may include A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-)A2-73 enantiomer, (+)A2-73 enantiomer, or any combination thereof. The A2-73 composition may be administered for a period of up to 14 weeks, such as about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks. The A2-73 composition may be administered daily, such as once a day. The A2-73 composition may include crystals of A2-73 or A2-73 free base, and may be administered in an amount of about 40 mg to about 60 mg once a day for about 6 weeks to about 11 weeks. For example, A2-73 is administered at about 50 mg a day for up to 11 weeks. Alternatively, A2-73 is administered once daily for 6 to 11 weeks at escalating doses starting at about 10 mg and ending at about 50 mg.
[0019] In any of the methods, the first and second biological samples may each be selected from a serum sample, a plasma sample, or any biological sample suitable for transcriptome analysis as disclosed herein.
[0020] Another aspect of the present disclosure includes a kit for medical use. The kit includes several containers, such as a first container for containing a first biological sample; a second container for containing a second biological sample; a third container and any additional containers useful for storing any reagent or component required for sequencing or measuring gene expression; and a container useful for storing a therapeutic compound or therapeutic composition described herein, such as any sigma-1 receptor agonist, such as A2-73 composition. The kit can also include instructions in printed or computer readable media that describe the method disclosed herein and the use of the kit to carry out the method.
[0021] For example, the kits disclosed herein may be used in any of the various methods disclosed, such as selecting a therapeutic agent for a subject, assessing the efficacy of a neurodegenerative treatment, identifying a subject responsive to sigma-1 receptor agonist therapy, or determining whether a subject has, is suspected of having, or is at high risk of developing a disorder or disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, nonalcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, or a disorder associated with myocardial contraction. In certain embodiments, the disease or disorder is Parkinson's disease or a prion disease.
[0022] The composition comprising the sigma-1 receptor agonist used in the kit may comprise ANAVEX2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX1-41, AV1066, ANAVEX3-71, PRE-084, L-687,384, SA-4503, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts. For example, the composition is an A2-73 oral composition comprising A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-)A2-73 enantiomer, (+)A2-73 enantiomer, or any combination thereof.
[0023] Another aspect of the disclosure encompasses a method of treating a disorder or disease in a subject by administering a therapeutically effective amount of a sigma-1 receptor agonist, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, a disorder associated with myocardial contraction, or any combination thereof. The sigma-1 receptor agonist may include ANAVEX2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX1-41, AV1066, ANAVEX3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts. For example, the sigma-1 receptor agonist may include A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-)A2-73 enantiomer, (+)A2-73 enantiomer, or any combination thereof. Also, the therapeutically effective amount of A2-73 includes A2-73 in an amount of 0.5 mg to 100 mg per day, for example 10 to 50 mg per day. In one embodiment, the treatment may be for the treatment of Parkinson's disease and includes administering an effective amount of A2-73 in an amount of about 10 mg to 50 mg per day. The A2-73 may be in the form of a free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-) A2-73 enantiomer, (+) A2-73 enantiomer, or any combination thereof. In another embodiment, the treatment may be for the treatment of prion disease and includes administering A2-73 in an amount of 0.5 mg to 100 mg per day. A2-73 can be in the form of the free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.The subject to be treated can be a human subject or a non-human mammal.
[0024] Color drawing reference The application file contains at least one photograph taken in color. Copies of this patent application publication with color photograph(s) will be provided by the Office upon request and payment of the necessary fee. [Brief description of the drawings]
[0025] [Figure 1] FIG. 1 is an exemplary overview of a Phase 2 proof-of-concept (PoC) study design for ANAVEX® 2-73 for treating Parkinson's Disease Dementia (PDD), including patient selection, endpoint information, and analytic methods.
[0026] [Figure 2A]1 is an exemplary overview of a multidisciplinary method for identifying gene response pathways of ANAVEX® 2-73 treatment. For gene clustering, WGCNA1 (Weighted Correlation Network Analysis) was used to cluster genes. Correlation networks are used in biology to analyze large amounts of high-dimensional data sets, starting from the correlation of TPM2 expression (transcripts / million; TPM values represent relative expression levels that should be comparable between samples) values between samples, and WGCNA created 17 clusters (size: 13-11,190 genes). Then, the eigengenes3 of the clusters (one of a set of gene matrices that aggregate the mRNA or gene expression of genes between samples) were used as a summary of the expression levels of the clusters. For cluster filtering, the eigengenes were used for each cluster as target variables in a linear mixed-effects model with three covariates: dose, patient, and time point. Clusters without significant (Dunnett's test) contrast between the treatment and placebo groups at all time points were excluded. The ratio of cluster size to the number of pathways was calculated, and the top two clusters were finally retained. For the biological description of the clusters, two approaches were tested. Figure 2A showed that the characterization and analysis were applied to all genes of the cluster (full cluster) and to genes of the cluster known to have biological interactions (reduced cluster). In the full cluster analysis, overrepresented pathways were identified using the EnrichR package with parameters of Fisher's adjusted p-value p<0.05 (Benjamini-Hochberg adjustment for multiple testing) and a minimum pathway size of 20. In the reduced cluster analysis, genes that do not interact with other genes of the cluster were discarded and the clusters were reduced. Pathway analysis was performed on these reduced clusters. The false discovery rate with adjustment for multiple testing (Benjamini-Hochberg method) was used to characterize the overrepresentation of pathways. Known interactions between genes of the cluster were evaluated using the STRING database with parameters of edge score >0.150 and without text mining edges.Known interactions were obtained from public databases such as KEGG, Panther, Allen, Brain Atlas, Gene Ontology, and Reactome. [Figure 2B] 1 is an exemplary overview of a multidisciplinary method for identifying gene response pathways of ANAVEX® 2-73 treatment. For gene clustering, WGCNA1 (Weighted Correlation Network Analysis) was used to cluster genes. Correlation networks are used in biology to analyze large amounts of high-dimensional data sets, starting from the correlation of TPM2 expression (transcripts / million; TPM values represent relative expression levels that should be comparable between samples) values between samples, and WGCNA created 17 clusters (size: 13-11,190 genes). Then, the eigengenes3 of the clusters (one of a set of gene matrices that aggregate the mRNA or gene expression of genes between samples) were used as a summary of the expression levels of the clusters. For cluster filtering, the eigengenes were used for each cluster as target variables in a linear mixed-effects model with three covariates: dose, patient, and time point. Clusters without significant (Dunnett's test) contrast between the treatment and placebo groups at all time points were excluded. The ratio of cluster size to the number of pathways was calculated, and the top two clusters were finally retained. For cluster biological description, two approaches were tested. Figure 2B showed that the functional interactions of each cluster between the genes of the cluster were assessed using the STRING database (edge score >0.150; no text mining edges). Genes that did not interact with other genes of the cluster were discarded and the clusters were reduced. Pathway enrichment analysis was performed on these reduced clusters. False discovery rate (FDR, adjusted for multiple testing using the Benjamini-Hochberg method) with adjustment for multiple testing was used to characterize the overrepresentation of pathways.
[0027] [Diagram 3]FIG. 13 is a log P-value plot of estimated marginal means for mixed models, where P-values are from Dunnett's test; linear mixed-effects model with three covariates: actual dose, patient, and time point.
[0028] [Figure 4A] Figure 4A shows the genes involved in the biological pathways of Parkinson's disease, prion disease, and Huntington's disease. FDR stands for false discovery rate, which is an adjustment for multiple testing using the Benjamini-Hochberg method. Only edges with a score >0.4 were shown. [Figure 4B] The interaction plot of genes in cluster 1 with 213 genes, p-values were calculated by Fisher's test. Figure 4B plots genes in KEGG 2022 pathways, which lists genes involved in biological pathways of Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases. This showed that of the 213 genes, 79% of genes (169) had biological interactions.
[0029] [Figure 5A] Figure 5A shows the interaction plot of genes in cluster 2 with 962 genes, which are involved in the biological pathways of degenerative diseases. FDR stands for false discovery rate, which is an adjustment for multiple testing using the Benjamini-Hochberg method. Figure 5B shows and lists genes with interaction score >0.4. [Figure 5B] Figure 5B shows that of the 962 genes in cluster 2, 70% of the genes (680) have biological interactions that correlate with Parkinson's disease, Alzheimer's disease, and other neurodegenerative diseases. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] The present disclosure is based in part on the discovery that a selected set of genes are differentially expressed when a subject is administered a therapeutic agent, such as a sigma-1 receptor agonist, for a period of time. Furthermore, these genes are involved in different biological pathways involved in specific diseases and disorders. The discovered correlations between disease treatment and changes in gene profiles (such as differentially expressed genes and / or over-represented gene clusters) before and after treatment may be used to further aid in selection regarding treatment. For example, the correlations may be used to evaluate the therapeutic efficacy of another therapeutic agent, or to select a therapeutic agent for a subject based on changes induced in gene profiling, or to use the therapeutic agent as a probe to assess the subject's disease state or risk of developing a disease. The present disclosure focuses on sigma receptor agonist therapy, which are related diseases and disorders. However, the same principles and methods may be applied to other types of therapeutic agents and diseases as well.
[0031] Sigma-1 receptors have been shown to be involved in higher brain functions, including memory and cognition. Thus, Sigma-1 receptor agonist therapy is often prescribed for patients with reduced memory or cognitive function, such as those with neurodegenerative disorders. It has been discovered that after a subject is treated with a Sigma-1 receptor agonist, the subject's gene expression profile changes, with a selected set of genes being differentially expressed and their associated gene clusters being overrepresented. The altered gene profile may be used as a benchmark to evaluate the therapeutic efficacy of another therapeutic agent. It may also be used to select a Sigma-1 receptor agonist for the subject. It may also be used to determine whether the subject is responsive to Sigma-1 receptor agonist therapy. Finally, Sigma-1 receptor agonists can be used to probe whether a subject has, is suspected of having, or is at high risk of having a disease associated with an altered gene expression profile.
[0032] I. Alterations in gene profiles associated with sigma-1 receptor agonist therapy The present inventors have found that a significant number of genes are differentially expressed after a period of sigma-1 receptor agonist therapy. These genes are divided into two clusters. The first gene cluster includes COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, and NDUFB3. The second gene cluster includes COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, and NDUF A12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6. Both clusters appear in several over-represented pathways related to various biological processes, dysfunctions, and diseases, such as neurodegenerative diseases and metabolic disorders. For example, the first gene cluster was found to be correlated with nine types of diseases or dysfunctions, five of which are neurodegenerative diseases. The nine diseases or dysfunctions are Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, oxidative phosphorylation dysfunction, and proteasome dysfunction. The second gene cluster is found to be correlated with 14 biological functions, diseases, or dysfunctions, five of which are neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, coronavirus disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, oxidative phosphorylation dysfunction, ribosome dysfunction, proteasome function, and thermogenic function.
[0033] Neurodegenerative diseases refer to hereditary and sporadic conditions characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of central or peripheral nervous system structures and may have symptoms in the form of cognitive impairment, memory loss, and motor disorders. Alzheimer's disease is a degenerative brain disease characterized by an insidious onset of dementia. Early symptoms include impairment of memory, judgment, attention span, and problem-solving abilities. In later stages, severe apraxia and total loss of cognitive abilities may occur. The disease is pathologically characterized by severe cortical atrophy and a triad of senile plaques, neurofibrillary tangles, and thread-like structures.
[0034] Parkinson's disease is a progressive degenerative neurological disorder characterized by tremor maximal at rest, retropulsion (i.e., tendency to fall backward), rigidity, stooped posture, slowness of spontaneous movement, and masked facial expression. Pathological features include loss of melanin-containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. Lewy bodies are present in the substantia nigra and locus coeruleus, but can also be found in associated conditions characterized by dementia in combination with varying degrees of parkinsonism. Symptoms of Parkinson's disease may include, but are not limited to, tremors and tremors, muscle rigidity, shuffling process, stooped posture, difficulty initiating movements, lack of facial expression, and dementia. Parkinson's disease dementia (PDD) is a decline in thinking and reasoning skills that develops in some people with Parkinson's disease. Parkinson's disease patients may have motor problems before the cognitive symptoms of dementia associated with Parkinson's disease. In Lewy body dementia, cognitive symptoms occur before or at the same time as motor problems. Secondary Parkinson's disease refers to a condition characterized by clinical symptoms similar to primary Parkinson's disease caused by known or suspected conditions, such as vascular injury, drugs, trauma, toxin exposure, neoplasms, infections, and degenerative or genetic conditions caused Parkinsonism. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. Tremor is generally less prominent in secondary Parkinsonism than in primary forms. As used herein, Parkinson's disease explicitly incorporates pathological features, clinical symptoms, symptoms, and any secondary Parkinson's disease. Specifically, Parkinson's disease as used herein explicitly incorporates Parkinson's disease dementia (PDD).
[0035] Huntington's disease is a familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive chorea and dementia in the fourth or fifth decade of life. Common early symptoms include delusional disorder, poor impulse control, depression, hallucinations, and delusions. Late symptoms include intellectual disability, loss of fine motor control, athetosis, and diffuse chorea affecting the axial and limb musculature, resulting in a vegetative state within 10 to 15 years of disease onset. Its juvenile variant has a more dramatic course including seizures, ataxia, dementia, and chorea. Amyotrophic lateral sclerosis is a degenerative disorder affecting the upper motor neurons of the brain and the lower motor neurons of the brainstem and spinal cord. Onset of the disease is usually after age 50, and the course is usually fatal within 3 to 6 years. Clinical symptoms include progressive weakness, atrophy, fasciculations, hyperreflexia, dysarthria, dysphagia, and eventual paralysis of respiratory function. Pathological features include replacement of motor neurons with fibrous astroglial cells and atrophy of the anterior spinal nerve roots and corticospinal tracts. Prion diseases are a group of hereditary, infectious, or sporadic human and animal degenerative nervous system disorders associated with abnormal forms of prions. These diseases are characterized by the conversion of normal prion protein to abnormal configurations through post-translational processes. In humans, these conditions are generally characterized by dementia, ataxia, and fatal outcomes. Pathological features include spongiform encephalopathies without evidence of inflammation. Some older literature may sometimes refer to these as non-conventional slow-onset viral infections.
[0036] Prion diseases, also called "transmissible spongiform encephalopathies" (TSEs), refer to a group of rare, progressive neurodegenerative disorders that affect both humans and animals. They are distinguished by a long incubation period, characteristic spongiform changes associated with neuronal loss, and an inability to induce an inflammatory response. The causative agent of TSEs is thought to be prions. The term "prion" refers to an abnormal pathogen that is transmissible and can induce the abnormal folding of certain normal cellular proteins called prion proteins, which are most abundantly found in the brain. The misfolding of the prion protein results in brain damage and the characteristic signs and symptoms of the disease. Prion diseases are usually rapidly progressive and invariably fatal. Human prion diseases include at least Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD), Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, and kuru. Animal prion diseases include at least bovine spongiform encephalopathy (BSE), chronic wasting disease (CWD), scrapie, transmissible mink encephalopathy, feline spongiform encephalopathy, and ungulate spongiform encephalopathy.
[0037] Amyotrophic lateral sclerosis or "ALS" is often also called Lou Gehrig's disease (after the baseball player who was diagnosed with it). It is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS often begins with muscle twitching and limb weakness, or slurred speech. The impact often begins in the hands, feet, or limbs, then spreads to other parts of the body. As the disease progresses and nerve cells are destroyed, the muscles become weaker. This eventually affects chewing, swallowing, speaking, and breathing. Symptoms include, but are not limited to, difficulty walking or performing normal daily activities, stumbling and falling, weakness in the legs, feet, or ankles, weakness or clumsiness in the hands, slurred speech or difficulty swallowing, muscle spasms and twitching of the arms, shoulders, and tongue, inappropriate shouting, laughing, or yawning, and cognitive and behavioral changes. There is no cure for this fatal disease.
[0038] Diabetic cardiomyopathy (DCM) is defined by the presence of abnormal myocardial structure and performance in individuals with diabetes mellitus, in the absence of other cardiac risk factors such as coronary artery disease, hypertension, and significant valvular disease. Altered metabolic state, impaired calcium homeostasis and energy production, increased inflammation and oxidative stress, and accumulation of advanced glycation end products are among the mechanisms involved in the pathogenesis of diabetic cardiomyopathy. Symptoms of DCM may include, but are not limited to, shortness of breath, fatigue, dizziness or fainting, arrhythmias (heart rate or rhythm problems), swelling of the feet and ankles, and chest pain. The minimum criteria for diagnosing DCM include left ventricular diastolic dysfunction and / or reduced left ventricular ejection fraction (EF), pathological left ventricular hypertrophy, and interstitial fibrosis.
[0039] Nonalcoholic fatty liver disease (NAFLD) is a set of chronic liver disorders, including nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), among others. NASH is a common cause of chronic liver disease and is defined as having at least 5% hepatic steatosis and inflammation with or without fibrosis. Over time, if untreated, NASH can progress to cirrhosis and even hepatocellular carcinoma (HCC). Furthermore, NAFLD / NASH are strongly associated with obesity and type II diabetes, both of which affect over 50% of the US population, resulting in a significant economic burden. Unfortunately, treatment options for NASH remain limited, with only modest benefits observed from vitamin E or obeticholic acid treatment. Although NASH is the leading cause of chronic liver disease and cirrhosis, there is currently no clinically approved treatment.
[0040] Coronavirus disease is a viral disorder caused by coronaviruses. It is generally characterized by high fever, cough, dyspnea, chills, persistent tremors, myalgia, headache, and viral pneumonia. Rare inflammatory syndromes can occur in younger patients, such as atypical Kawasaki syndrome, toxic shock syndrome, pediatric multisystem inflammatory disease, and cytokine storm syndrome. COVID-19 and SARS (severe acute respiratory syndrome) are two severe forms of coronavirus disease. Diabetic cardiomyopathy is a diabetic complication in which ventricular remodeling in the absence of coronary atherosclerosis and hypertension results in cardiac dysfunction, usually left ventricular dysfunction. This change also leads to myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance. Nonalcoholic fatty liver disease refers to fatty liver findings without excessive alcohol intake. Fatty liver is the lipid infiltration of hepatic parenchymal cells, resulting in a yellow liver. Abnormal lipid accumulation is usually in the form of triglycerides as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of fatty acids. Oxidative phosphorylation dysfunction refers to any dysfunction or deficiency in the process of electron transfer through the cytochrome system, which releases free energy that is converted into high-energy phosphate bonds. Oxidative phosphorylation dysfunction can cause a group of clinically heterogeneous diseases that are generally defined by a lack of cellular energy due to defects in oxidative phosphorylation resulting from pathogenic mutations in nuclear DNA, such as lactic acidosis, which indicates an overproduction of lactate and / or a decrease in lactate metabolism. Ribosomes have two main functions: decoding messages and forming peptide bonds. Ribosomes are important for proper protein synthesis. Ribosome dysfunction constitutes a collection of disorders in which genetic abnormalities cause impairment of ribosome biogenesis and ribosome function, resulting in specific clinical phenotypes. Proteasomes are multi-subunit enzyme complexes that play a central role in the regulation of proteins that control cell cycle progression and apoptosis. Impairment of the proteasome can lead to many diseases, including cancer and a wide range of chronic neurodegenerative diseases. Thermogenesis, which refers to the dissipation of energy through the production of heat, occurs in specialized tissues, including brown adipose tissue and skeletal muscle.Some hormones, such as norepinephrine and leptin, can stimulate body heat production by activating the sympathetic nervous system. Thermogenic dysfunction can affect normal lipid metabolism and fat regulation, which in turn leads to metabolic syndrome or disorder.
[0041] Other diseases or disorders encompassed by the present disclosure include, but are not limited to, disorders associated with thermogenesis, disorders associated with oxidative phosphorylation, disorders associated with proteasome dysfunction, disorders associated with ribosomal dysfunction, disorders associated with retrograde endocannabinoid signaling, and disorders associated with myocardial contraction.
[0042] II. Methods of Use: Alterations in Genetic Profiles Associated with Sigma-1 Receptor Agonist Therapy Certain aspects of the present disclosure include methods of selecting a therapeutic agent for a subject suffering from a disease or disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, a disorder associated with myocardial contraction, etc. It is understood that any of the methods disclosed herein include actions that may be performed in any reasonable order or sequence.
[0043] One aspect of the method includes obtaining or obtaining a first biological sample from a subject, administering a sigma receptor agonist to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed and overrepresented genes. (i) identifying a gene cluster comprising: (a) a first gene cluster including COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; or (b) identifying a gene cluster including COX4I1, NDUFB11, PSMA7, COX6A, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; 1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11 , NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCR H, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6, or (ii) the identified overrepresented gene cluster overlaps with genes listed in the first gene cluster or genes listed in the second gene cluster, selecting a sigma receptor agonist as a therapeutic agent for the subject.
[0044] Another aspect of the present disclosure includes a method of assessing the effectiveness of a neurodegenerative therapy in a subject in need thereof.The method includes obtaining or obtaining a first biological sample from a subject, administering a neurodegenerative therapy to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the treatment period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters. and (i) identifying a differentially expressed gene that is a gene listed in a first gene cluster that includes COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7. , PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SL C25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDU or (ii) the identified overrepresented gene cluster overlaps with genes listed in the first gene cluster or genes listed in the second gene cluster, or identifying the neurodegenerative treatment as efficacious for the subject if either condition (i) or (ii) is not observed.
[0045] Yet another aspect of the disclosure includes a method of identifying a subject responsive to sigma-1 receptor agonist therapy. The method includes obtaining or obtaining a first biological sample from a subject, administering a sigma receptor agonist to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed and overrepresented genes. and identifying a gene cluster (differentially expressed in a gene cluster), with the following proviso: (i) the identified differentially expressed genes are genes listed in a first gene cluster including COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or COX4I1, NDUFB11, PSMA7, COX6A1, NDUF B2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUF S3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, ND and identifying the subject as responsive to sigma-1 receptor agonist therapy if any one of the following is observed: (i) the identified overrepresented gene cluster is a gene listed in a second gene cluster comprising UFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) the identified overrepresented gene cluster overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster.
[0046] In any of the methods described herein, the subject is a human subject having or suspected of having a disorder or disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, or a disorder associated with myocardial contraction.
[0047] In various aspects, if a neurodegenerative therapy is identified as ineffective for a subject, follow-up measures may include switching to an alternative neurodegenerative therapy, supplementing with an alternative neurodegenerative therapy, adjusting the dosage if the neurodegenerative therapy is a drug therapy, or switching to a combination neurodegenerative therapy.
[0048] The neurodegenerative treatment can be sigma-1 receptor agonist therapy, or NMDA therapy, or cognitive enhancement physical therapy.For example, the neurodegenerative treatment can be a drug therapy that includes sigma-1 receptor agonist, such as ANAVEX2-73 (A2-73), ANAVEX 19-144, ANAVEX1-41, AV1066, ANAVEX3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharmaceutically acceptable salts.
[0049] As used herein, ANAVEX 2-73 (A2-73) has the chemical name tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride. A2-73 free base has the chemical name tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine. ANAVEX 19-144 (A19-144) has the chemical name 1-(2,2-diphenyltetrahydrofuran-3-yl)-N-methylmethanamine hydrochloride. ANAVEX 1-41 (A1-41) has the chemical name tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride. AV1066 has the chemical name 1-(3-4(((1R,3S,5S)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine. ANAVEX3-71 (A3-71, AF-710B) has the chemical name 1-(2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]decan-3-yl)-3-(1H-indol-3-yl)propan-1-one.
[0050] In various aspects of the method, the neurodegeneration treatment is A2-73 drug therapy, including administration of A2-73 free base, amorphous form of A2-73, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-) A2-73 enantiomer, or (+) A2-73 enantiomer. The present disclosure encompasses crystalline polymorphs of A2-73. The crystalline polymorphs may be prepared by solvent extraction or supercritical fluid extraction (SCE). Crystalline forms prepared from solvent extraction are described in PCT / US2019 / 027369 (filed April 12, 2019), published as International Publication WO2019200345. Crystalline forms prepared by SCE extraction are described in PCT / IB2016 / 001181 (filed July 19, 2016), published as International Publication No. WO 2017013498. The entire contents of both PCT / US2019 / 027369 and PCT / IB2016 / 001181 are incorporated herein by reference. The present disclosure expressly encompasses A2-73 crystalline form I, A2-73 crystalline form II, and A2-73 crystalline form III prepared and characterized in PCT / IB2016 / 001181. A2-73 crystalline form I is a crystal having the XRPD peaks shown in FIG. 1. A2-73 crystalline form I is further characterized by the scanning electron microscope (SEM) micrographs shown in FIGS. 2-3. A2-73 crystalline form II is a crystal having the XRPD peaks shown in FIG. 4. A2-73 crystalline form II is also characterized by FTIR as shown in Figure 5. A SEM micrograph of A2-73 crystalline form II is shown in Figure 7. A2-73 crystalline form III is a crystal with XRPD peaks shown in Figure 8. A2-73 crystalline form III is characterized by FTIR as shown in Figure 9. A2-73 crystalline form III is characterized by a scanning electron microscope (SEM) micrograph as shown in Figure 11. The present disclosure also encompasses crystalline polymorphs of A2-73 free base. Crystalline polymorphs of A2-73 free base are described in PCT / US2019 / 027369 (filed April 12, 2019), published as International Publication No. WO 2019200345. As an example, a crystalline form of A2-73 free base is a crystalline form characterized by an XRPD pattern as shown in Figure 16. Such a crystalline form has a particle shape as shown in Figure 15.The present disclosure encompasses the enantiomers of A2-73 or mixtures of such enantiomers. The enantiomers may be (+) or (-) enantiomers. Enantiomers refer to optically pure entities or substantially optically pure entities. Substantially optically pure entities refer to the opposite rotating entities may be present in an amount of 20% or less, such as at or about 0.1%, 0.5% or about 0.5%, 1% or about 1%, 2% or about 2%, 5% or about 5%, 8% or about 8%, 10% or about 10%, 12% or about 12%, 15% or about 15%, 18% or about 18%, 20% or about 20%. The present disclosure expressly encompasses the (+) and (-) enantiomers disclosed and characterized in PCT / IB2016 / 001158, filed July 19, 2016, published as U.S. Patent Application Publication No. 20180169059. The entire contents of PCT / IB2016 / 001158 are expressly incorporated herein by reference.
[0051] In yet another aspect of the disclosure, the neurodegenerative therapy or sigma-1 receptor agonist may be administered or administered for a period of up to 14 weeks, such as about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks. Also, the therapeutic agent is administered daily, such as once a day.
[0052] In yet another aspect of the disclosure, the neurodegenerative treatment is a drug therapy comprising a composition comprising A2-73, e.g., a crystalline form of A2-73, administered in an amount of about 40 mg to about 60 mg once a day for about 6 weeks to about 11 weeks. For example, A2-73 is administered at about 50 mg daily for up to 11 weeks. Alternatively, A2-73 is administered daily at escalating doses starting at about 10 mg and ending at about 50 mg once a day for a period of 6 weeks to 11 weeks.
[0053] III. Methods of Using Sigma-1 Receptor Agonists One aspect of the disclosure encompasses a method of determining whether a subject has or is suspected of having a disease or disorder, or a method of assessing a subject's risk of developing such a disease or disorder, e.g., the disorder or disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, or a disorder associated with myocardial contraction.In one aspect, a method includes obtaining or obtaining a first biological sample from a subject, administering a composition of ANAVEX 2-73 to the subject for a period of time, obtaining or obtaining a second biological sample from the subject at the end of the administration period, determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample, comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed and overrepresented genes. and identifying a differentially expressed gene cluster comprising: (i) a first gene cluster including COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; or (ii) a first gene cluster including COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMA7, COX6A1, NDUFB2, PSMA8, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3; MB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A , NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQC or (ii) the identified overrepresented gene cluster overlaps with the genes listed in the first gene cluster or the genes listed in the second gene cluster, identifying the subject as having or at increased risk for developing the disorder or disease described above.
[0054] As with all methods disclosed herein, the composition of A2-73 may include A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
[0055] In any method, a composition comprising A2-73 can be administered to a subject for a period of up to 14 weeks, e.g., 2-3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks. The therapeutic agent is administered daily, e.g., once a day.
[0056] In any of the methods, the A2-73 composition may include a crystal of A2-73 or A2-73 free base, administered in an amount of about 40 mg to about 60 mg once a day for a period of about 6 weeks to about 11 weeks. For example, the crystal of A2-73 or A2-73 free base is administered at about 50 mg / day for up to 11 weeks. Alternatively, A2-73 or A2-73 free base is administered daily at escalating doses starting at about 10 mg and ending at about 50 mg once a day for 6 to 11 weeks.
[0057] In yet another aspect of the present disclosure, the method includes a biological sample. The biological sample may include solid, semi-solid, semi-fluid, fluid, tissue, or other material collected from a subject. The biological sample may be a fluid biological sample. A fluid biological sample may include a fluid and some or all of the cells, particles, crystals, and other components in the fluid. Examples of biological samples include, but are not limited to, blood, serum, plasma, bone marrow, nasal swabs, nasopharyngeal washings, saliva, urine, gastric fluid, spinal fluid, tears, stool, mucus, sweat, earwax, oil, glandular secretions, cerebrospinal fluid, tissue, semen, vaginal fluid, interstitial fluid from tumor tissue, ocular fluid, spinal fluid, throat swabs, exhaled breath, hair, fingernails, skin, biopsy, placental fluid, amniotic fluid, umbilical cord blood, lymphatic fluid, cavity fluid, sputum, pus, microbiota, meconium, breast milk, and / or other secretions or excretions. Biological samples may include nasopharyngeal washings or other fluids obtained by washing a body cavity or surface of a subject, or by washing a swab after applying the swab to a body cavity or surface of a subject. Nasal swabs, throat swabs, stool samples, hair, nails, ear wax, breath, and other solid, semi-solid, or gas samples may be treated in an extraction buffer, for example, for a fixed or variable time. Examples of subject tissue samples may include, but are not limited to, connective tissue, muscle tissue, nerve tissue, epithelial tissue, cartilage, cancer samples, or bone. Samples may be obtained from humans or animals. Samples may be obtained from vertebrates, for example, birds, fish, or mammals, such as rats, mice, pigs, apes, other primates (including humans), farm animals, sports animals, or pets. Samples may be obtained from living or dead subjects. Samples may be obtained fresh from a subject or may have undergone some form of pre-processing, storage, or transportation. The terms "blood" and "whole blood" refer to blood present in an animal and obtained directly from a subject in a blood sample. Blood includes red blood cells, white blood cells, proteins such as albumin, globulins, clotting factors, salts, water, and other components. A blood sample is a fluid biological sample. In one aspect, a biological sample refers to a fluid sample that contains suspended cells, cellular material, fungi, antigens, biological agents, immunogens, proteins, and other materials of biological origin that have sizes substantially larger than the sizes of the molecules that generally comprise fluids.Biological factors refer to compounds made by or associated with an organism that have biological or physiological activity. Biological factors include, but are not limited to, biological markers, antibodies, cytokines, growth factors, and other biologically produced peptides, proteins, lipids, and carbohydrates. The terms "plasma" and "blood plasma" refer to the liquid portion of blood (e.g., a blood sample) that remains after removal of blood cells. Red and white blood cells can be removed by centrifugation of the blood sample, leaving the plasma above the pelleted cells at the bottom of the centrifuge tube. Plasma retains blood clotting factors and is obtained from anticoagulated blood samples. A sample of plasma is a fluid biological sample. The terms "serum" and "blood serum" refer to the liquid portion of blood that remains after allowing blood to clot and removing the clot. Serum differs from plasma in that serum lacks clotting factors, whereas plasma contains fibrin, thrombin, and other proteins that remain part of the clot, as these proteins are required for clotting. A sample of serum is a fluid biological sample. The present disclosure includes a first biological sample and / or a second biological sample. The first biological sample and the second biological sample may be the same type of biological sample, but may be taken at different times. The first biological sample and the second biological sample may be different types of biological samples taken from the same subject. The first biological sample and the second biological sample may be different types of biological samples taken from the same subject at different times. The first biological sample and the second biological sample may be the same type of biological sample taken at the same time, but from different subjects. The first biological sample and the second biological sample are each independently any biological sample listed above. In an embodiment, the first biological sample and the second biological sample are each independently a serum sample, a plasma sample, or a biological sample suitable for transcriptome analysis. Transcriptome analysis is the examination of the transcriptome, the complete set of RNA transcripts produced by a genome, under a particular situation or in a particular cell, often using high-throughput methods.Transcriptome analysis is useful for identifying gene functions and / or pathways that respond to or ameliorate environmental stress. RNA-Seq may also identify disease-associated gene fusions, single nucleotide polymorphisms, and even allele-specific expression. The present disclosure expressly incorporates any biological sample that is suitable for and / or may be used for transcriptome analysis.
[0058] IV. Kits and Medical Uses Certain aspects of the present disclosure include kits for medical use according to any of the monitoring, evaluation, or treatment selection methods disclosed herein. Kits for such use include one or more containers for containing and holding biological samples that may be taken at different time points, and reagents for performing gene expression analysis. For example, the kit may have a first container for containing a first biological sample as used in the disclosed method; a second container for containing a second biological sample as used in the disclosed method; and an additional one or more containers for containing and / or storing reagents useful for sequencing or measuring gene expression. Additional containers may be included to contain and store compositions in a safe, stable, and durable manner. The composition may include a composition comprising a sigma-1 receptor agonist, such as A2-73 or A2-73 free base. The kit may include instructions in hard copy printed or computer readable form that describe the use of the kit components to perform any of the methods described herein. The instructions may be written for the intended reader, the physician and / or the patient.
[0059] In certain aspects of the present disclosure, the kits may be used for a variety of purposes, such as selecting a therapeutic agent for a subject, assessing the effectiveness of a neurodegenerative treatment, identifying a subject who will respond to sigma-1 receptor agonist therapy, or determining whether a subject has, is suspected of having, or is at high risk of developing a disorder or disease. Such disorders or diseases may include, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosome dysfunction, a disorder associated with retrograde endocannabinoid signaling, or a disorder associated with myocardial contraction.
[0060] V. Treatment method Certain aspects of the present disclosure include methods of treating a disorder or disease in a subject by administering a therapeutically effective amount of a sigma-1 receptor agonist, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, a disorder associated with myocardial contraction, or any combination thereof. Sigma-1 receptor agonists may include any of the following: ANAVEX 2-73 (A2-73), ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687, 384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts. In some embodiments, the treatment is treatment of Parkinson's disease or prion disease.
[0061] In any of these treatment methods, the sigma-1 receptor agonist may be A2-73 in the form of A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, (-) A2-73 enantiomer, (+) A2-73 enantiomer, or any combination thereof. Also, the therapeutically effective amount of A2-73 includes A2-73 in an amount of 0.5 to 100 mg per day, for example, 10 to 50 mg per day. A2-73, the therapeutically effective amount of A2-73 may be in the range of about 0.5 mg to about 20 mg, about 1 mg to about 60 mg, about 30 mg to about 50 mg, or about 3 mg to about 5 mg. A therapeutically effective amount of A2-73 may range from about 0.5 mg / day to about 100 mg / day, from about 1 mg / day to about 60 mg / day, from about 20 mg / day to about 50 mg / day, from about 20 mg / day to about 30 mg / day, or from about 15 mg / day to about 25 mg / day. Administering an anti-neurodegenerative effective amount of A2-73 may provide blood levels of A2-73 of about 10 ng / ml, about 12 ng / ml.
[0062] A2-73 may be administered to the subject daily, or more than once a day. Additionally, A2-73 may be administered every 2, 3, 4, 5, 6, 7, 14, or 30 days. A2-73 may be administered for a period ranging from about 1 day to about 1 year, about 1 day to about 1 week, about 3 days to about 1 month, about 2 weeks to about 6 months, or about 2 months to about 4 months. A2-73 may also be administered for about 1 day, about 7 days, about 30 days, about 60 days, about 120 days, or about 180 days, or longer. In some embodiments, A2-73 is administered for about 6 weeks, 8 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 57 weeks, about 148 weeks, about 208 weeks, indefinitely, or until resolution of the condition being treated.
[0063] Other methods of administering A2-73 are described, for example, in U.S. Patent No. 9,750,746, U.S. Patent Application Publication No. 20170360798, U.S. Patent Application Publication No. 20190022052, U.S. Patent Application Publication No. 20180360796, U.S. Patent Application Publication No. 20180169059, U.S. Patent Application Publication No. 20180177756, U.S. Patent Application Publication No. 20180169060, and U.S. Patent Application Publication No. 20190117615, the disclosures of which are incorporated herein in their entireties.
[0064] VI. Biological Materials and Methods Any biological sample suitable for transcriptome or genetic analysis may be used in the present disclosure. Non-limiting examples of suitable biological samples include bodily fluid samples, biopsy samples, skin samples, and hair samples. Fluid samples may include blood, serum, plasma, saliva, tears, and lymphatic fluid. In some aspects, the biological sample is a blood sample, a serum sample, a plasma sample, or any transcriptome sample. Methods for obtaining biological samples from subjects are well known in the art.
[0065] Gene expression measurements include both DNA and RNA measurements. They can be achieved by various methods, including Northern blotting, quantitative real-time PCR (qRT-PCR), nucleic acid microarrays, Luminex microspheres, and nuclease protection assays. Methods for determining substantially different levels of RNA expression are known in the art and include distribution analysis. In some embodiments, substantially different levels of RNA expression are determined by normalizing RNA expression values as transcripts per Kilobase Million (TPM).
[0066] VII. Pharmaceutical Compositions Certain aspects of the present disclosure include pharmaceutical compositions comprising a neurodegenerative agent and / or a sigma-1 receptor agonist. The pharmaceutical composition comprises a therapeutically effective amount of an active pharmaceutical ingredient, and any pharma-ceutical acceptable salts thereof.
[0067] Pharmaceutically acceptable salts include, but are not limited to, acetate, aspartate, benzoate, bitartrate, citrate, formate, gluconate, glucuronate, glutamate, fumarate, hydrochloride, hydrobromide, hydroiodide, hypophosphite, isobutyrate, isocitrate, lactate, malate, maleate, meconate, methyl bromide, methanesulfonate, monohydrate, mucate, nitrate, oxalate, phenylpropionate, phosphate, phthalate, propionate, pyruvate, salicylate, stearate, succinate, sulfate, tannate, tartrate, terephthalate, and valerate salts.
[0068] When the pharma- ceutical active ingredient is A2-73, the composition may contain about 1 mg to about 50 g, about 0.1 g to about 5 g, about 0.5 g to about 3 g, about 1 mg to about 55 mg, about 40 mg to about 60 mg, about 80 mg to about 120 mg, about 180 mg to about 220 mg, about 0.1 g to about 5 g, or about 0.5 g to about 3 g of A2-73. Formulations comprising A2-73 can be found, for example, in U.S. Patent No. 9,750,746, U.S. Patent Application Publication No. 20170360798, U.S. Patent Application Publication No. 20190022052, U.S. Patent Application Publication No. 20180360796, U.S. Patent Application Publication No. 20180169059, U.S. Patent Application Publication No. 20180177756, U.S. Patent Application Publication No. 20180169060, and U.S. Patent Application Publication No. 20190117615, the disclosures of which are incorporated herein in their entireties.
[0069] The active pharmaceutical ingredient can be formulated and administered to a subject by several different means. For example, the composition can be usually administered parenterally, intraperitoneally, intravascularly, transdermally, subcutaneously, or intrapulmonary in a dosage unit formulation, optionally containing conventional non-toxic pharmacologic acceptable adjuvants, carriers, excipienets, and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrathecal, or intrasternal injection or infusion techniques. The formulation of pharmaceutical compositions is described, for example, in Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.(1975), and Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY(1980).
[0070] The pharmaceutical composition also includes one or more pharma- ceutically acceptable non-medicinal ingredients. Non-limiting examples of non-medicinal ingredients include chemical enhancers, humectants, pressure-sensitive adhesives, antioxidants, solubilizers, thickeners, plasticizers, adjuvants, carriers, excipients, vehicles, coatings, and any combination thereof. The non-medicinal ingredient(s) may be selected for oral, transdermal, parenteral, intraperitoneal, intravascular, subcutaneous, inhalation spray, rectal, or pulmonary administration.
[0071] Active pharmaceutical ingredients may generally be formulated to improve patient compliance and prevent subjects from removing the drug delivery device. For example, sigma-1 receptor agonists may be formulated to improve patient compliance and prevent removal of the drug delivery device by providing a formulation for extended delivery. Extended delivery may span a period ranging from more than one day to several months. This may be particularly relevant for patients with reduced cognitive and / or motor control abilities. Extended delivery over a period may range from about 1 day to about 1 year, about 1 day to about 1 week, about 3 days to about 1 month, about 2 weeks to about 6 months, or about 2 months to about 4 months.
[0072] Sustained release formulations may be used for substantially continuous delivery of the drug at a preselected rate. For example, in the case of crystalline A2-73, the drug may be delivered at a rate of about 1 mg / day to about 100 mg / day, about 40 mg / day to about 60 mg / day, or about 10 mg / day to about 30 mg / day. The appropriate amount of crystalline A2-73 may be readily determined by one of skill in the art based, for example, on the intended period of administration of the drug via the sustained release formulation, the delivery mechanism, the particular formulation, and the relative potency of the drug, among other factors.
[0073] Binder Non-limiting examples of binders suitable for the various embodiments of the formulation include starch, pregelatinized starch, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamide, polyvinyloxazolidone, polyvinyl alcohol, C12-C18 fatty acid alcohols, polyethylene glycol, polyols, saccharides, oligosaccharides, polypeptides, oligopeptides, and combinations thereof. Polypeptides can be any sequence of amino acids ranging from about 100 to about 300,000 daltons.
[0074] The binder may be introduced into the mixture to be granulated in a solid form, including but not limited to crystals, particles, powder, or any other finely divided solid form known in the art, or may be dissolved or suspended in a solvent and sprayed into the mixture in the granulation equipment as a binder fluid during granulation.
[0075] Diluent Non-limiting examples of diluents (also called "fillers" or "thinners") include carbohydrates, inorganic compounds, and biocompatible polymers such as polyvinylpyrrolidone (PVP). Other non-limiting examples of diluents include dibasic calcium sulfate, tribasic calcium sulfate, starch, calcium carbonate, magnesium carbonate, microcrystalline cellulose, dibasic calcium phosphate, tribasic calcium phosphate, magnesium carbonate, magnesium oxide, calcium silicate, talc, modified starches, sugars such as sucrose, dextrose, lactose, microcrystalline cellulose, fructose, xylitol, and sorbitol, polyhydric alcohols; starches; pre-fabricated direct compression diluents; and mixtures of any of the foregoing.
[0076] Disintegrants Disintegrants can be effervescent or non-effervescent.Non-limiting examples of non-effervescent disintegrants include starches such as corn starch, potato starch, pregelatinized starch and modified starches thereof, sweeteners, clays such as bentonite, microcrystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar, carob, karaya, pectin and tragacanth.Suitable effervescent disintegrants include, but are not limited to, sodium bicarbonate in combination with citric acid and sodium bicarbonate in combination with tartaric acid.
[0077] Preservatives Non-limiting examples of preservatives include ascorbic acid and its salts, ascorbyl palmitate, ascorbyl stearate, anoxomer, N-acetylcysteine, benzyl isothiocyanate, m-aminobenzoic acid, o-aminobenzoic acid, p-aminobenzoic acid (PABA), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), caffeic acid, canthaxanthin, α-carotene, β-carotene, β-carotene, β-carotene, β-apocarotenic acid, carnosol, carvacrol, catecholamines ... cinnamon, cetyl gallate, chlorogenic acid, citric acid and its salts, clove extract, coffee bean extract, p-coumaric acid, 3,4-dihydroxybenzoic acid, N,N'-diphenyl-p-phenylenediamine (DPPD), thiodilauryl thiodipropionate, distearyl thiodipropionate, 2,6-di-tert-butylphenol, dodecyl gallate, edetic acid, ellagic acid, erythorbic acid, sodium erythorbate, esculetin, esculin, 6-ethoxy-1,2-dihydro-2,2,4-tetrahydrofuran, ... Trimethylquinoline, Ethyl gallate, Ethyl maltol, Ethylenediaminetetraacetic acid (EDTA), Eucalyptus extract, Eugenol, Ferulic acid, Flavonoids (e.g., catechin, epicatechin, epicatechin gallate, epigallocatechin (EGC), epigallocatechin gallate (EGCG), polyphenol epigallocatechin-3-gallate), Flavones (e.g., apigenin, chrysin, luteolin), Flavonols (e.g., dacisin, myricetin, demferro), Flavanones, Fraxin, Fucos ... Malic acid, gallic acid, gentian extract, gluconic acid, glycine, guaiacum, hesperetin, alpha-hydroxybenzylphosphinic acid, hydroxycinnamic acid, hydroxyglutaric acid, hydroquinone, N-hydroxysuccinic acid, hydroxytolylsol, hydroxyurea, rice bran extract, lactic acid and its salts, lecithin, lecithin citrate; R-alpha-lipoic acid, lutein, lycopene, malic acid, maltol, 5-methoxytryptamine, methyl gallate, monoglyceride citrate; monoisopropyl citrate;Morin, beta-naphthoflavone, nordihydroguaiaretic acid (NDGA), octyl gallate, oxalic acid, palmityl citrate, phenothiazine, phosphatidylcholine, phosphoric acid, phosphate salts, phytic acid, phytyl bichromel, pimento extract, propyl gallate, polyphosphate salts, quercetin, trans-resveratrol, rosemary extract, rosmarinic acid, sage extract, sesamol, silymarin, sinapic acid, succinic acid, stearyl citrate, syringic acid, tartaric acid, thymol, tocopherols (i.e., α-tocopherol, β-tocopherol, γ-tocopherol, and δ-tocopherol), tocotrienols (i.e., α-tocotrienol, β-tocopherol, γ-tocopherol, and δ-tocopherol), -tocotrienol, gamma-tocotrienol, and delta-tocotrienol), tyrosol, vanillic acid, 2,6-di-tert-butyl-4-hydroxymethylphenol (i.e., Ionox 100), 2,4-(tris-3',5'-bi-tert-butyl-4'-hydroxybenzyl)-mesitylene (i.e., Ionox 330), 2,4,5-trihydroxybutyrophenone, ubiquinone, tertiary butylhydroquinone (TBHQ), thiodipropionic acid, trihydroxybutyrophenone, tryptamine, tyramine, uric acid, vitamin K and derivatives, vitamin Q10, wheat germ oil, zeaxanthin, or combinations thereof;
[0078] Flavor Modifiers Suitable flavor modifiers include flavoring agents, flavoring agents, sweeteners, etc. Flavoring agents include, but are not limited to, synthetic flavor oils and flavoring aromatics and / or natural oils, extracts from plants, leaves, flowers, fruits, and combinations thereof. Other non-limiting examples of flavors include cinnamon oil, oil of wintergreen, peppermint oil, clover oil, hay oil, anise oil, eucalyptus, vanilla, citrus oils such as lemon oil, orange oil, grape and grapefruit oil, fruit extracts including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
[0079] Flavoring agents include cellulose hydroxypropyl ethers (HPC), such as Klucel®, Nisswo HPC, and PrimaFlo HP22; low-substituted hydroxypropyl ethers (L-HPC); cellulose hydroxypropyl methyl ethers (HPMC), such as Seppifilm-LC, Pharmacoat®, Metolose SR, Opadry YS, PrimaFlo, MP3295A, Benecel MP824, and Benecel MP843; methylcellulose polymers, such as Methocel® and Metolose®; ethylcellulose (EC) and mixtures thereof, such as E461, Ethocel®, Aqualon®-EC, Surelease; polyvinyl alcohol (PVA), such as Opadry AMB; hydroxyethylcellulose, such as Natrosol®; carboxymethylcellulose and salts of carboxymethylcellulose (CMC), such as Aualon®-CMC; polyvinyl alcohol and polyethylene glycol copolymers, such as Kollicoat®. IR®; monoglycerides (Myverol), triglycerides (KLX), polyethylene glycol, modified food starch, acrylic polymers, and mixtures of acrylic polymers and cellulose ethers such as Eudragit® EPO, Eudragit® RD100, and Eudragit® E100; cellulose acetate phthalate; mixtures of HPMC and stearic acid, cyclodextrins, and sepifilm, such as mixtures of these materials. In other aspects, additional flavoring agents contemplated include those described in U.S. Pat. Nos. 4,851,226; 5,075,114; and 5,876,759, each of which is incorporated herein by reference in its entirety.
[0080] Non-limiting examples of sweeteners include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts such as its sodium salt; dipeptide sweeteners such as aspartame; dihydrochalcone compounds, glycyrrhizin; stevia (stevioside); chloro derivatives of sucrose such as sucralose; sugar alcohols such as sorbitol, mannitol, sulitol, hydrogenated starch hydrolysates, and the synthetic sweetener 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, especially the potassium salt (acesulfame-K), as well as the sodium and calcium salts thereof.
[0081] Lubricants and glidants The lubricant composition may be utilized to lubricate the components forming the pharmaceutical composition. As a glidant, the lubricant facilitates removal of the solid dosage form during the manufacturing process. Non-limiting examples of lubricants and glidants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil. The pharmaceutical composition generally comprises about 0.01% to about 10% by weight of the lubricant. In some embodiments, the pharmaceutical composition comprises about 0.1% to about 5% by weight of the lubricant. In further embodiments, the pharmaceutical composition comprises about 0.5% to about 2% by weight of the lubricant.
[0082] Dispersants Dispersing agents may include, but are not limited to, high hydrophilic-lipophilic balance (HLB) emulsifier surfactants such as starch, alginic acid, polyvinylpyrrolidone, guar gum, kaolin, bentonite, refined wood cellulose, sodium starch glycolate, and the like amorphous silicates, and microcrystalline cellulose.
[0083] Coloring agent Depending on the embodiment of the present disclosure, it may be desirable to include a coloring agent. Suitable color additives include, but are not limited to, Food, Drug, and Cosmetic Colorants (FD&C), Drug and Cosmetic Colorants (D&C), or Extrinsic Drug and Cosmetic Colorants (Ext. D&C). These colorants or dyes, along with their corresponding lakes, and certain natural and derived colorants, may be suitable for use in various embodiments of the present disclosure.
[0084] pH adjuster Non-limiting examples of pH adjusters include citric acid, acetic acid, tartaric acid, malic acid, fumaric acid, lactic acid, phosphoric acid, sorbic acid, benzoic acid, sodium carbonate, and sodium bicarbonate.
[0085] Chelating Agents Chelating agents may be included as excipients for immobilizing oxidized groups, including but not limited to metal ions to inhibit oxidative degradation of the morphinan by these oxidized groups. Non-limiting examples of chelating agents include lysine, methionine, glycine, gluconic acid, polysaccharides, glutamic acid, aspartic acid, and disodium ethylenediaminetetraacetate (Na2EDTA).
[0086] Antibacterial agents Antimicrobial agents may be included as non-medicinal ingredients to minimize degradation of the disclosed compounds by microbial agents, including (but not limited to) bacteria and fungi. Non-limiting examples of antimicrobial agents include parabens, chlorobutanol, phenol, calcium propionate, sodium nitrate, sodium nitrite, Na2EDTA, and sulfites (including but not limited to sulfur dioxide, sodium bisulfite, and potassium bisulfite).
[0087] Controlled Release Polymers Release-controlling polymers may be included in various embodiments of solid-dose pharmaceutical compositions incorporating the compounds of the present disclosure. In some embodiments, release-controlling polymers may be used as tablet coatings. In other embodiments, including (but not limited to) bilayer tablets, release-controlling polymers may be mixed with granules and other excipients and then formed into tablets by known methods, including (but not limited to) compression in tablet molds. Suitable release-controlling polymers include, but are not limited to, hydrophilic polymers and hydrophobic polymers.
[0088] Suitable hydrophilic release-controlling polymers include, but are not limited to, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose ethers, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, nitrocellulose, crosslinked starch, agar, casein, chitin, collagen, gelatin, maltose, mannitol, maltodextrin, pectin, pullulan, sorbitol, xylitol, polysaccharides, ammonia alginate, sodium alginate, calcium alginate, potassium alginate, propylene glycol alginate, sodium carmellose alginate, calcium carmellose, carrageenan, fucoidan, furcellaran, gum arabic, carrageen gum, guffti gum, guar gum, calcium cellulose ... raya gum, locust bean gum, okra gum, tragacanth gum, scleroglucan gum, xanthan gum, hipan gum, laminaran, acrylic polymers, acrylate polymers, carboxyvinyl polymers, copolymers of maleic anhydride and styrene, copolymers of maleic anhydride and ethylene, copolymers of propylene maleic anhydride or copolymers of isobutylene maleic anhydride, crosslinked polyvinyl alcohol and poly N-vinyl-2-pyrrolidone, diesters of polyglucan, polyacrylamides, polyacrylic acids, polyamides, polyethylene glycols, polyethylene oxides, poly(hydroxyalkyl methacrylates), polyvinyl acetates, polyvinyl alcohols, polyvinyl chloride, polystyrene, polyvinylpyrrolidone, anionic and cationic hydrogels, and combinations thereof.
[0089] coating A solid dosage containing a compound according to the present disclosure may include a coating, such a coating may control the release of the compound, act as a moisture barrier, act as a buffer, or modify the pH. As used herein, a "controlled release coat" or "controlled release coat" is defined to mean a functional coat that may include, for example, at least one pH-independent polymer, pH-dependent polymer (e.g., enteric or reverse enteric type polymer), soluble polymer, insoluble polymer, lipid, lipid material, or combinations thereof. When applied to a dosage form, the coating may slow (e.g., when applied to a normal release matrix dosage form), further slow (e.g., when applied to a controlled release matrix dosage form), or modify the release rate of a compound according to the present disclosure when applied to an uncoated dosage form. For example, a controlled release coat may be designed such that when the controlled release coat is applied to a dosage form, the dosage form in combination with the controlled release coat may exhibit a release of a compound according to the present disclosure such as "modified release", "controlled release", "sustained release", "extended release", "delayed release", "extended release", or combinations thereof. The "control-releasing coat" may optionally include additional materials that may alter the functionality of the control-releasing coat.
[0090] The term "moisture barrier" as used herein is one that prevents or retards the absorption of moisture. Compounds according to the present disclosure may be hygroscopic and therefore may be susceptible to degradation over time under high humidity conditions. The proportion of components of the moisture barrier and the amount of moisture barrier optionally applied on the controlled release coating or on the core are typically such that the moisture barrier does not fall within the USP definition and requirements of the enteric coat. Suitably, the moisture barrier may comprise an enteric and / or acrylic polymer, suitably an acrylic polymer, optionally a plasticizer, and a permeation enhancer. The permeation enhancer is a hydrophilic material that allows water to enter without physically destroying the coating. The moisture barrier may further comprise other conventional inert excipients that may improve the processing of the sustained release formulation.
[0091] Coating and matrix materials that may be used in accordance with the present disclosure are those known in the art for use in controlled release formulations, such as synthetic polymers of the polyvinyl type, e.g., polyvinyl chloride, polyvinyl acetate and their copolymers, polyvinyl alcohol, and polyvinylpyrrolidone; synthetic polymers of the polyethylene type, such as polyethylene and polystyrene; acrylic acid polymers; biopolymers or modified biopolymers, e.g., cellulose polymers, shellac, and gelatin; fats, oils, higher fatty acids and higher alcohols (i.e., acids and alcohols containing an alkyl chain of at least 10 carbon atoms), e.g., aluminum monostearate, cetyl alcohol, hydrogenated tallow, hydrogenated castor oil, 12-hydroxystearic alcohol, glyceryl mono- or dipalmitate; glyceryl mono-, di-, or tristearate; myristyl alcohol, stearic acid, stearyl alcohol, polyethylene glycol; waxes; sugars and sugar alcohols.
[0092] The pH buffering properties of the coating may be enhanced by the incorporation into the coating of a material selected from the group of compounds commonly used in antacid formulations, such as magnesium oxide, hydroxide or carbonate, aluminum or calcium hydroxide, carbonate or silicate; complex aluminum / magnesium compounds, such as Al2O3·6MgO·CO2·12H2O, (Mg6Al2(OH)16CO3·4H2O), MgO·Al2O3·2SiO2·nH2O, aluminum bicarbonate coprecipitate or similar compounds; or other pharma- ceutically acceptable pH buffering compounds, such as the sodium, potassium, calcium, magnesium and aluminum salts of phosphoric acid, carbonate, citric acid or other suitable weak, inorganic or organic acids; or suitable organic bases, including basic amino acids; and salts or combinations thereof.
[0093] A pH-dependent coating serves to release the drug in the desired region of the gastrointestinal (GI) tract, such as the stomach or small intestine. If a pH-independent coating is desired, the coating is designed to achieve optimal release regardless of pH changes in the environmental fluid, such as the GI tract. When the coating is formulated to release the compound of the present disclosure in the intestine, particularly the upper small intestine, the coating is often referred to as an "enteric coating." The pH-dependent coating may include, but is not limited to, acrylic acid polymers and copolymers, such as acrylic acid, methacrylic acid, methyl acrylate, ammoniomethyl acrylate, ethyl acrylate, methyl methacrylate and / or ethyl methacrylate (e.g., Eudragit®); cellulose polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cellulose acetate phthalate (CAP), cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose succinate, and sodium carboxymethylcellulose; shellac (purified lac); vinyl polymers and copolymers such as polyvinylpyrrolidone, polyvinyl acetate, polyvinyl acetate phthalate (PVAP), vinyl acetate-crotonic acid copolymer, and ethylene-vinyl acetate copolymer; zein; and polymers formed from salts and combinations thereof. Oral tables and capsules typically have a coating.
[0094] definition Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which this disclosure belongs. The following references provide those skilled in the art with general definitions of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed.1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R.Rieger et al.(eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them unless otherwise specified.
[0095] When introducing elements of the disclosure or preferred aspect(s) thereof, the articles "a," "an," "the," and "said" are intended to mean that there are one or more elements. The terms "comprising," "including," and "having" are intended to be inclusive and mean that there may be additional elements other than the listed elements.
[0096] Since various modifications can be made to the above cells and methods without departing from the scope of the present disclosure, it is intended that all matter contained in the above description and in the examples given below should be interpreted in an illustrative and not a limiting sense.
[0097] The term "comprising" means "including, but not necessarily limited to," and it specifically indicates open-ended inclusion or membership in such listed combinations, groups, series, and the like. As used herein, the terms "comprising" and "including" are inclusive and / or open-ended and do not exclude additional unrecited elements or method steps. The term "consisting essentially of" is more restrictive than "comprising," but not as restrictive as "consisting of." Specifically, the term "consisting essentially of" limits membership to the specified materials or items, and those that do not materially affect the essential characteristics of the disclosure.
[0098] As used herein, the term "gene" refers to a segment of DNA that contains all the information for the regulated biosynthesis of an RNA product, including promoters, exons, introns, and other untranslated regions that control expression. As used herein, "expression" includes, but is not limited to, one or more of the following: transcription of a gene into precursor mRNA; splicing and other processing of the precursor mRNA to produce a mature mRNA; mRNA stability; translation of the mature mRNA into a protein (including codon usage and tRNA availability); and glycosylation and / or other modifications of the translation product, if required for proper expression and function. As used herein, the term "differentially expressed genes" refers to a statistically significant difference or change in the expression levels of a gene in two experimental conditions or two samples. As used herein, the term "overrepresented" genes or gene clusters refers to the presence of more genes from a given set than expected.
[0099] As used herein, the term "transcriptome analysis" refers to characterizing transcriptional activity (coding and non-coding), focusing on a subset of relevant target genes and transcripts, or profiling thousands of genes at once to create a genetic profile. As used herein, the term "mutant" refers to any genetic variation from wild type that is the result of mutations, such as single nucleotide polymorphisms ("SNPs") and insertions / deletions. The term "mutant" is used interchangeably with the terms "marker," "biomarker," and "target" throughout this specification.
[0100] As used herein, the term "polynucleotide" refers to any RNA or DNA, which may be unmodified or modified RNA or DNA. Polynucleotides include, but are not limited to, single-stranded and double-stranded DNA, DNA that is a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA, RNA that is a mixture of single-stranded and double-stranded regions, and hybrid molecules containing DNA and RNA that may be single-stranded or more typically double-stranded or a mixture of single-stranded and double-stranded regions. Furthermore, polynucleotide refers to triple-stranded regions that include RNA or DNA or both RNA and DNA. The term polynucleotide also includes DNA or RNA that contains one or more modified bases, and DNA or RNA with backbones that are modified for stability or other reasons.
[0101] As used herein, the term "polypeptide" refers to any polypeptide comprising two or more amino acids linked together by peptide bonds or modified peptide bonds, i.e., peptide isosteres. Polypeptides refer to both short chains, commonly referred to as peptides, glycopeptides or oligomers, and to longer chains, commonly referred to as proteins. Polypeptides can contain amino acids other than the 20 gene-encoded amino acids. Polypeptides include amino acid sequences modified by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and more detailed monographs, as well as in a voluminous research literature.
[0102] As used herein, the terms "disease", "disorder" or "dysfunction" are used interchangeably in this disclosure. They refer to any condition, disorder, or disease that manifests as one or more physiological, physical and / or psychological symptoms or dysfunctions for which treatment is desired, including previously identified and newly identified diseases, disorders, or dysfunctions of any organ, tissue, or biological activity. As used herein, the term "medical use" is any use or procedure related to restoring, improving, or preserving the health or wellness of a subject.
[0103] As used herein, the term "subject" means that the subject is preferably a mammal such as a human, but may also be an animal, such as domestic animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, sheep, pigs, horses, etc.), and laboratory animals (e.g., cynomolgus monkeys, rats, mice, guinea pigs, etc.).
[0104] As used herein, administration of an agent or drug to a subject or patient includes self-administration and administration by another. The various modes of treatment or prevention of medical conditions as described are intended to mean "substantially", which includes complete treatment or prevention, although it should also be understood that some biologically or medically relevant result is achieved that is less than complete treatment or prevention.
[0105] The above publications are provided solely for their disclosure prior to the filing date of the present application, and nothing herein should be construed as an admission that the present disclosure is not entitled to antedate such disclosure by virtue of prior disclosure.
[0106] Working Example The following examples are included to demonstrate the present disclosure. Those skilled in the art should understand that the techniques disclosed in the following examples represent the techniques discovered by the inventors to work well in the implementation of the present disclosure. However, those skilled in the art should understand in light of the present disclosure that many changes can be made in the present disclosure and still obtain the same or similar results without departing from the spirit and scope of the present disclosure, and therefore all matters described should be interpreted as illustrative and not in a limiting sense.
[0107] Example 1 ANAVEX® 2-73 ANAVEX® 2-73 (Bralcamesine), an agonist of the sigma-1 receptor (SIGMAR1), has mechanistically focused new targets relevant to Alzheimer's, Parkinson's, and other neurological disorders. SIGMAR1 activation is a compensatory mechanism for chronic CNS disease. Direct occupancy of ANAVEX® 2-73 at SIGMAR1 has been established using quantitative PET scans. Full genomic analysis of the ANAVEX® 2-73-PDD-001 Phase 2 study in Parkinson's Disease Dementia (PDD) patients evaluated biomarkers of response to explore the potential of Precision Medicine approaches. The overall goal of this study was to identify ANAVEX® 2-73 responsive pathways by identifying the most differentially expressed genes and characterizing the pathways involved.
[0108] Example 2 Study Design of ANAVEX® 2-73 to Treat Parkinson's Disease A Phase 2 study, coded as "ANAVEX® 2-73-PDD-001 Study" (Figure 1), was conducted to evaluate the safety, tolerability, and efficacy of ANAVEX® 2-73 (bularcamesin) oral capsules in treating cognitive impairment in patients with Parkinson's disease with dementia (PDD). The study was a three-arm, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The study included a 2-week screening / baseline observation period and a 14-week treatment period (including a 2-week titration period), as well as a 2-week safety follow-up period. A total of 132 patients were enrolled in the study and randomly assigned to the three study arms (Figure 1). In the ANAVEX 2-73 high-dose arm, 44 patients received ANAVEX 2-73 oral capsules once daily at escalating doses of 10 mg, 20 mg, 30 mg, and 50 mg. In the ANAVEX 2-73 mid-dose group, 44 patients received oral capsules of ANAVEX 2-73 once daily at escalating doses of 10 mg, 20 mg, and 30 mg. In the placebo group, 44 patients received placebo capsules. Outcome measures included the Cognitive Drug Research (CDR) Computerized Assessment System for continuum of attention; change from baseline to end of treatment in continuum of attention as measured by the Cognitive Drug Research (CDR) Computerized Assessment System for continuum of attention; number of participants with treatment-related adverse events assessed by CTCAE v4.0 [time frame: 14 weeks]; evaluation of the safety and tolerability of ANAVEX2-73 compared to placebo; MDS-UPDRS Part III total score (motor score); change from baseline to end of treatment as measured by MDS-UPDRS Part III total score (motor score); SDS-CL-25 [time frame: 14 weeks]; incidence of sleep disorder symptoms (SDS-CL-25); and DNA / RNA sequencing.
[0109] The study enrolled 132 adults (aged 50-85 years) with PDD and was successfully completed in September 2020. Participants, recruited at multiple sites in Spain and Australia, were randomly assigned to one of two dose groups (with ANAVEX 2-73 oral capsules in ascending doses up to 30 mg or 50 mg) or placebo, once daily (see Figure 1 for details) for a period of 14 weeks. The primary objective of the study was to evaluate the safety of the treatment and changes in patients' cognitive function, measured using the Computerized Assessment System for Cognitive Drug Testing (a test examining multiple cognitive skills such as choice reaction time (choosing between similar objects), vigilance, and episodic memory (remembering new personal experiences or shared information)). Secondary objectives included changes in patients' motor skills (assessed with the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III) and sleep quality. Previously reported results showed that ANAVEX 2-73 was generally safe, significantly improved some cognitive skills, and reduced REM sleep behavior disorder, in which patients physically act while dreaming. This sleep disorder is associated with greater cognitive impairment and a higher risk of dementia. Data from the current trial confirmed these cognitive and sleep benefits and showed that a high dose of treatment (50 mg) resulted in a statistically significant and clinically meaningful reduction in motor and non-motor parkinsonian symptoms, as assessed by the MDS-UPDRS total score. After 14 weeks, the MDS-UPDRS total score had decreased by 10.98 points in the high-dose group (indicating a reduction in disease severity) and increased by 3.53 points in the placebo group. This represented an adjusted mean improvement of 14.51 points (above the established clinically meaningful 7.1 point cutoff) and a relative improvement of 18.9% over 14 weeks. These findings highlight the ability of ANAVEX 2-73 to not only slow but also reverse progressive symptoms in Parkinson's disease, potentially filling an urgent unmet medical need, Anavex said in its announcement.Patients' use of ANAVEX2-73 also resulted in a significant increase in SIGMAR1 levels, an increase significantly associated with improved attention measures, and a reduction in both MDS-UPDRS total and MDS-UPDRS Part III (motor score). Overall, these data confirmed the mechanism of action of the treatment and supported SIGMAR1 as a biomarker of clinical response to ANAVEX2-73. After completing the PDD-001 study, patients had the option to be treated with ANAVEX2-73 for nearly one year in its extension study, called ANAVEX2-73-PDD-EP-001 (NCT04575259).
[0110] Example 3 Patient Genome Sequencing and ANAVEX2-73 Response Pathway To gain insight into ANAVEX2-73 response pathways, DNA and RNA sequencing of patients were analyzed during the phase 2 study. Transcriptome samples of 65 patients enrolled in either the high or medium dose group were collected at baseline and end of treatment (week 14). Expression of 14,150 genes was measured. No transformation was applied to TPM values. Values associated with a RIN ≤ 4.0 were discarded. The actual dose of ANAVEX2-73 (bularcamesin) administered to each patient during the study was evaluated and integrated into the database. To characterize gene dysregulation, a pathway database was constructed using a collection of public databases including KEGG, Panther, Allen, Brain Atlas, Gene Ontology, and Reactome.
[0111] Specifically, as shown in Figure 2A, RNA sequencing was performed on 130 collected samples to measure the expression of 14,150 genes. Starting from the correlation of TPM expression values between samples, genes were clustered using WGCNA. This gene clustering resulted in 17 clusters with sizes ranging from 13 to 11,190 genes. The TPM expression values of genes in the clusters were then aggregated into a single "eigengene" for each cluster. This eigengene served as a representative of the overall dysregulation of the cluster. Secondly, cluster filtering was performed taking into account the patient group and dose information based on a mixed-effects model. For each cluster, the eigengene was used as the target variable in a linear mixed-effects model with three covariates: actual dose, patient, and time point. For each cluster, the control actual dose, i.e., treatment vs. placebo, was evaluated across all time points. P-values were obtained using Dunnett's test. To compensate for the large variability in the size of the clusters and the corresponding variability in the number of pathways identified in each cluster, regardless of cluster and pathway, pathways with less than four genes in the cluster were removed. The ratio of cluster size to number of pathways was calculated, and the top two clusters were retained for further analysis. Cluster 1 contained 213 genes (n1=213) and 37 pathways, while cluster 2 contained 962 genes (n2=962) and 317 pathways. Both clusters had dysregulation significantly associated with the highest dose of ANAVEX2-73 (bularcamesin). Third, the two retained clusters were characterized and pathway analysis was performed. Characterization and analysis was applied to all genes of the cluster (full cluster) and genes of the cluster known to have biological interactions (reduced cluster). In the full cluster analysis, overrepresented pathways were identified using the EnrichR package with parameters of Fisher's adjusted p-value p<0.05 (Benjamini-Hochberg adjustment for multiple testing) and a minimum pathway size of 20. In the reduced cluster analysis, genes that did not interact with other genes of the cluster were discarded and the clusters were reduced.Pathway analysis was performed on these reduced clusters. False discovery rate with adjustment for multiple testing (Benjamini-Hochberg method) was used to characterize pathway overrepresentation. Known interactions between genes of the clusters were assessed using parameters of edge score >0.150 and the STRING database without text mining edges. Known interactions were obtained from public databases such as KEGG, Panther, Allen, Brain Atlas, Gene Ontology, and Reactome.
[0112] As shown in Figure 3, significant associations were identified between treatment and estimated marginal mean expression of the six clusters. These means were larger in the significant clusters, confirming the impact of ANAVEX® 2-73 on the expression of these clusters. In the first cluster, of its 37 pathways, 10 pathways were significantly over-represented, and six of them were found to be related to neurodevelopmental diseases. In addition, 76% of the genes included in cluster 1 (164 genes out of 213 genes in cluster 1) were known to have biological interactions. These 164 genes were significantly enriched for Parkinson's, prion, and Huntington's disease pathways (FDR(1)=0.003). For cluster 2, of its 317 pathways, 10 pathways were significantly over-represented, and six of them were found to be related to neurodevelopmental diseases. In addition, 76% of the genes included in cluster 1 (164 genes out of 213 genes in cluster 1) were known to have biological interactions. These 164 genes were significantly enriched for Parkinson's, prion, and Huntington's disease pathways (FDR(1)=0.003). [Table 1]
[0113] In the second cluster, of its 317 pathways, 15 pathways were significantly over-represented, and 6 of them were found to be related to neurodevelopmental diseases (Figure 5A). Furthermore, 74 brain regions were significantly over-represented in the second cluster (n2=962 genes). Of these 74, 11 regions were related to the olfactory bulb, which is known to be a common symptom of PD and AD. In addition, 70% of the genes included in cluster 1 (680 genes out of 967 genes in cluster 2) were known to have biological interactions. These 680 genes were significantly enriched in Parkinson's disease pathways (FDR(1)<0.001). [Table 2] [Table 3]
[0114] Example 4 RNA sequencing analysis to identify the impact of treatment on compensatory pathways in PDD Whole blood transcriptomics analysis (RNA sequencing) of Parkinson's Disease Dementia (PDD) patients was performed for the ANAVEX® 2-73-PDD-001 study (Figure 1) at two time points: baseline and week 14 (end of study). All available RNA samples with RIN > 41 (RNA Integrity Number using 130 samples) were analyzed. Expression of 14,150 genes at these two time points was analyzed from both placebo and ANAVEX® 2-73 treated patients.
[0115] The above method was performed as shown in Figure 2B. For gene clustering, WGCNA1 (Weighted Correlation Network Analysis) was used to cluster genes. Correlation networks are used in biology to analyze large high-dimensional data sets starting from the correlation of TPM2 expression (transcripts / million. TPM values represent relative expression levels that should be comparable between samples) values between samples, and WGCNA created 17 clusters (size: 13-11,190 genes). Then, the eigengenes3 of the clusters (one of a set of gene matrices that aggregate the mRNA or gene expression of genes between samples) were used as a summary of the expression levels of the clusters. For cluster filtering, the eigengenes were used for each cluster as the target variable in a linear mixed-effects model with three covariates: dose, patient, and time point. Clusters without significant (Dunnett's test) contrast between the treatment group and the placebo group at all time points were excluded. The ratio of cluster size to the number of pathways was calculated, and the top two clusters were finally retained. For the biological description of the clusters, the functional interactions of each cluster between the genes of the cluster were assessed using the STRING database (edge score >0.150; no text mining edges). Genes that did not interact with other genes of the cluster were discarded and the clusters were reduced. Pathway enrichment analysis was performed on these reduced clusters. False discovery rate (FDR, adjusted for multiple testing using the Benjamini-Hochberg method) with adjustment for multiple testing was used to characterize pathway overrepresentation.
[0116] A randomized, placebo-controlled clinical trial in 132 patients with Parkinson's disease dementia (PDD) included collection of pre-identified biomarkers of response, as well as whole-exome sequencing DNA data and whole-RNA exome expression data. The study demonstrated dose-dependent, statistically significant improvement in episodic memory with ANAVEX® 2-73, as well as significant improvement in Parkinson's disease assessment, MDS-UPDRS total score (p=0.034), for patients treated with high oral doses of ANAVEX® 2-73 once daily during the 14-week study.
[0117] ANAVEX® 2-73 transcriptomics analysis (RNA sequencing) identified a gene network that was differentially expressed in Parkinson's disease dementia (PDD) patients treated with ANAVEX® 2-73 compared to placebo after 14 weeks of treatment. The biological relevance of this gene network was evaluated by pathway analysis to confirm the impact of ANAVEX® 2-73 treatment on pathways involved in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease. In the two clusters of genes affected by ANAVEX® 2-73, more than 70% of the genes are known to have biological interactions. Pathway enrichment analysis revealed that multiple neurodegenerative pathways, including Alzheimer's disease and Parkinson's disease, were significantly enriched for these genes (adjusted p-value <0.005), as shown in Figure 4B and Figure 5B. Both identified clusters were upregulated in treated patients compared to placebo, and the eigengene expression of cluster 2 was significantly increased in patients treated with high oral dose ANAVEX® 2-73 compared to placebo (p=0.021). These genes are known to be downregulated in both Alzheimer's and Parkinson's disease pathologies. Therefore, it is reasonable to conclude that the expression levels of dysregulated neurodegenerative genes were restored by the therapeutic effect of ANAVEX® 2-73.
[0118] In summary, this study identified a unique set of genes affected by ANAVEX2-73 (Bralcamesin) treatment. The genes were differentially expressed and their respective expression correlated with various neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, nonalcoholic fatty liver disease, coronavirus disease, disorders associated with thermogenesis, disorders associated with oxidative phosphorylation, disorders associated with proteasome dysfunction, disorders associated with ribosomal dysfunction, disorders associated with retrograde endocannabinoid signaling, and disorders associated with myocardial contraction. Pathway analysis confirmed the impact of treatment on pathways involved in neurodegenerative diseases as well as associations between ANAVEX2-73 (Bralcamesin) and genes differentially expressed across multiple brain regions. Characterization of ANAVEX2-73 (Bralcamesin) response pathways identified opportunities for translational identification of potential indications for ANAVEX2-73 (Bralcamesin), including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, disorders associated with thermogenesis, disorders associated with oxidative phosphorylation, disorders associated with proteasome dysfunction, disorders associated with ribosomal dysfunction, disorders associated with retrograde endocannabinoid signaling, and disorders associated with myocardial contraction.
[0119] These results provide guidance and facilitation for contextualizing future readouts for ANAVEX® 2-73 Phase 2b / 3 Alzheimer's disease clinical trials. These findings further support pivotal trials in Parkinson's disease and Parkinson's dementia. These findings also enable translational identification of additional potential therapeutic indications for ANAVEX® 2-73.
[0120] The results showed that genes are downregulated in Alzheimer's and Parkinson's diseases, but ANAVEX® 2-73 specifically affected the expression levels of these genes in multiple pathways by counteracting the pathological downregulation of genes in both Alzheimer's disease (p<0.005) and Parkinson's disease (p<0.005), as well as other degenerative diseases (p<0.005), which may represent further potential biomarkers of disease pathology and response.
Claims
1. 1. A method of selecting a therapeutic agent for a subject suffering from a disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction, comprising: a. obtaining or having obtained a first biological sample from said subject; b. administering to said subject a sigma receptor agonist for a period of time; c. obtaining or having obtained a second biological sample from the subject at the end of the administration period; d. determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample; e. comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters; f. (i) any of the identified differentially expressed genes is a gene listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or is any of the genes listed in a first gene cluster comprising COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, or if the gene is listed in a second gene cluster including PSMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) if any of the identified overrepresented gene clusters overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster; selecting said sigma receptor agonist as a therapeutic agent for said subject; The method comprising:
2. 2. The method of claim 1, wherein the sigma receptor agonist comprises a compound selected from ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687,384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, and any crystalline forms, enantiomers, and pharma- ceutically acceptable salts thereof.
3. 2. The method of claim 1, wherein the sigma receptor agonist comprises A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, or the (+) A2-73 enantiomer.
4. The method according to any one of claims 1 to 3, wherein the period in (b) is 14 weeks or less.
5. 5. The method of claim 1, wherein the period of time in (b) is about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks.
6. The method of any one of claims 1 to 5, wherein the sigma receptor agonist is administered daily.
7. 7. The method of any one of claims 1 to 6, wherein the sigma receptor agonist comprises A2-73, and the A2-73 is administered daily in an amount of about 40 mg to about 60 mg for a period of 6 to 14 weeks.
8. 7. The method of any one of claims 1 to 6, wherein the sigma receptor agonist comprises A2-73 in a crystalline form, and the A2-73 is administered in an amount of about 50 mg once daily for a period of up to 11 weeks.
9. 10. The method of claim 1, wherein said sigma receptor agonist comprises a crystalline form of A2-73, and said A2-73 is administered once daily for a period of 11 weeks in escalating doses starting at about 10 mg and ending at about 50 mg.
10. 1. A method for assessing the effectiveness of a neurodegenerative therapy in a subject in need thereof, comprising: a. obtaining or having obtained a first biological sample from said subject prior to initiation of said neurodegenerative therapy; b. providing said neurodegenerative therapy to said subject for a period of time; c. obtaining or having obtained a second biological sample from said subject at the end of said neurodegenerative therapy period; d. determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample; e. comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters from the measured gene expression profiles; f. (i) any of the identified differentially expressed genes is a gene listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or any of COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PS or if the gene is a gene listed in a second gene cluster including MB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) if any of the identified overrepresented gene clusters overlaps with a gene of the first gene cluster or a gene of the second gene cluster; identifying the neurodegenerative treatment as effective in the subject; or identifying the neurodegenerative treatment as ineffective for the subject if neither (i) nor (ii) is observed; The method comprising:
11. If the neurodegenerative treatment is identified as ineffective in (f), the method further comprises: i. switching to another neurodegenerative treatment; ii. Supplementation with another neurodegenerative treatment; iii. if the neurodegenerative treatment comprises drug therapy, adjusting the dose; iv. Switching to a combination neurodegenerative therapy; The method of claim 10 , further comprising one or more of:
12. 12. The method of claim 10 or claim 11, wherein the subject is a human subject having or suspected of having a neurodegenerative disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion diseases, and any combination thereof.
13. 13. The method of any one of claims 10 to 12, wherein the neurodegenerative treatment comprises a medication selected from any of ANAVEX 2-73 (A2-73), ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687,384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, and crystalline forms, enantiomers, and pharma- ceutically acceptable salts thereof.
14. 14. The method of any one of claims 10 to 13, wherein the neurodegenerative therapy is selected from medications comprising A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, and the (+) A2-73 enantiomer.
15. The method according to any one of claims 10 to 14, wherein the period is up to 14 weeks.
16. 16. The method of any one of claims 10 to 15, wherein the period is about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks.
17. The method of any one of claims 10 to 16, wherein the neurodegenerative therapy is administered daily.
18. 18. The method of any one of claims 10 to 17, wherein said neurodegeneration therapy comprises A2-73 pharmacotherapy, said A2-73 pharmacotherapy comprising daily administration of A2-73 or A2-73 free base in an amount of about 40 mg to about 60 mg for a period of 6 weeks to 14 weeks.
19. 18. The method of any one of claims 10 to 17, wherein said neurodegeneration therapy comprises A2-73 pharmacotherapy, said A2-73 pharmacotherapy comprising administration of a crystalline form of A2-73 or A2-73 free base once daily in an amount of about 50 mg for a period of up to 11 weeks.
20. 18. The method of any one of claims 10 to 17, wherein said neurodegenerative therapy comprises A2-73 pharmacotherapy, said A2-73 pharmacotherapy comprising administering escalating amounts of a crystalline form of A2-73 once daily for a period of 11 weeks, starting at about 10 mg and ending at about 50 mg.
21. 1. A method for identifying a subject responsive to sigma-1 receptor agonist therapy, comprising: a. obtaining or having obtained a first biological sample of said subject; b. providing said subject with said sigma-1 receptor agonist therapy for a period of time; c. obtaining or having obtained a second biological sample from said subject at the end of the administration period of (b); d. determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample; e. comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters; f. (i) any of the identified differentially expressed genes is selected from the group consisting of genes listed in a first gene cluster including COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or any of the genes listed in a first gene cluster including COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, P or if the gene is listed in a second gene cluster including SMB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFBl, PSMA2, NDUFBlO, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) if any of the identified overrepresented gene clusters overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster; identifying said subject as responsive to said sigma-1 receptor agonist therapy; A method comprising:
22. 22. The method of claim 21, wherein the sigma-1 receptor agonist therapy is a medication selected from any of ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, L-687,384, SA-4503, dimethyltryptamine, (+)-pentazocine, and crystalline forms, enantiomers, and pharma- ceutically acceptable salts thereof.
23. 22. The method of claim 21, wherein the sigma-1 receptor agonist therapy is A2-73 medication comprising administration of A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
24. 24. The method of any one of claims 21 to 23, wherein the subject is a human subject having or suspected of having a disorder selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, a disorder associated with myocardial contraction, and any combination thereof.
25. The method according to any one of claims 21 to 24, wherein the period is up to 14 weeks.
26. 26. The method of any one of claims 21 to 25, wherein the period is about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks.
27. The method of any one of claims 21 to 26, wherein the sigma-1 receptor agonist therapy is provided daily.
28. 28. The method of any one of claims 21 to 27, wherein said sigma-1 receptor agonist therapy comprises A2-73 medication, said A2-73 medication comprising daily administration of an amount of about 40 mg to about 60 mg of A2-73 or A2-73 free base for a period of 6 weeks to 14 weeks.
29. 28. The method of any one of claims 21 to 27, wherein said sigma-1 receptor agonist therapy is A2-73 medication, and said A2-73 medication comprises administering a crystalline form of A2-73 or A2-73 free base once daily in an amount of about 50 mg for a period of up to 11 weeks.
30. 28. The method of any one of claims 21-27, wherein said sigma-1 receptor agonist therapy comprises A2-73 medication, said A2-73 medication comprising administering A2-73 or a crystalline form of A2-73 free base once daily for a period of 11 weeks in escalating doses starting at about 10 mg and ending at about 50 mg.
31. 1. A method for determining whether a subject has or is suspected of having a disease, comprising: a. obtaining or having obtained a first biological sample of said subject; b. administering to said subject a composition of A2-73 for a period of time; c. obtaining or having obtained a second biological sample from the subject at the end of the administration period; d. determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample; e. comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters; f. (i) any of the identified differentially expressed genes is a gene listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or a gene listed in a first gene cluster comprising COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PS or if the gene is a gene listed in a second gene cluster including MB6, COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) if any of the identified overrepresented gene clusters overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster; identifying said subject as having said disease; Including, The disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction. method.
32. 32. The method of claim 31, wherein the composition of A2-73 comprises A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
33. The method of claims 31-32, wherein the composition of A2-73 comprises an oral composition.
34. The method according to any one of claims 31 to 33, wherein the period is up to 14 weeks.
35. 35. The method of any one of claims 31 to 34, wherein the period is about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks.
36. The method of any one of claims 31 to 35, wherein the A2-73 composition is administered daily.
37. The method of any one of claims 31 to 36, wherein the A2-73 composition is administered in an amount of about 40 mg to about 60 mg daily for a period of 6 to 14 weeks.
38. 37. The method of any one of claims 31 to 36, wherein the A2-73 composition comprises a crystalline form of A2-73 or A2-73 free base and is administered in an amount of about 50 mg once daily for a period of up to 11 weeks.
39. 37. The method of any one of claims 31-36, wherein the A2-73 composition comprises a crystalline form of A2-73 or A2-73 free base and is administered once daily in escalating doses starting at about 10 mg and ending at about 50 mg for a period of up to 11 weeks.
40. 1. A method of assessing a subject's risk of developing a disease selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction, comprising: a. obtaining or having obtained a first biological sample of said subject; b. administering to said subject a composition of ANAVEX2-73 for a period of time; c. obtaining or having obtained a second biological sample from said subject at the end of the administration period; d. determining a gene expression profile for the first biological sample and a gene expression profile for the second biological sample; e. comparing the gene expression profile of the first biological sample to the gene expression profile of the second biological sample to identify differentially expressed genes and overrepresented gene clusters; f. (i) the identified differentially expressed genes are genes listed in a first gene cluster comprising COX5B, COX7B, COX8A, NDUFB6, TXN, PSMA4, CLTB, PSMB3, POLR2F, NDUFA1, PSMD13, POLR2, NDUFA2, DDIT3, CYBA, AGER, MAPA2K2, PSENEN, or NDUFB3, or COX4I1, NDUFB11, PSMA7, COX6A1, NDUFB2, PSMB1, COX6B1, NDUFB7, PSMB4, COX6C, NDUFB8, PSMB5, COX7A2, NDUFB9, PSMB6 , COX7C, NDUFC1, PSMB7, CYC1, NDUFC2, PSMD8, NDUFA11, NDUFS3, RPS27A, NDUFA12, NDUFS4, SLC25A6, NDUFA13, NDUFS5, TXN2, NDUFA3, NDUFS6, UQCR10, NDUFA4, NDUFS7, UQCR11, NDUFA7, NDUFS8, UQCRH, NDUFA8, PARK7, UQCRQ, NDUFB1, PSMA2, NDUFB10, CDK5, GAPDH, HRAS, HSD17B10, or PSMA6; or (ii) if any of the identified overrepresented gene clusters overlaps with a gene listed in the first gene cluster or a gene listed in the second gene cluster; identifying the subject as being at high risk for developing the disease; A method comprising:
41. 41. The method of claim 40, wherein the composition of A2-73 comprises A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
42. The method of claims 40-41, wherein the composition of A2-73 comprises an oral composition.
43. 43. The method of any one of claims 40 to 42, wherein the period is up to 14 weeks.
44. 44. The method of any one of claims 40 to 43, wherein the period is about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 13 weeks, or about 14 weeks.
45. The method of any one of claims 40 to 44, wherein the A2-73 composition is administered daily.
46. The method of any one of claims 40 to 45, wherein the A2-73 composition is administered in an amount of about 40 mg to about 60 mg daily for a period of 6 to 14 weeks.
47. 46. The method of any one of claims 40 to 45, wherein the A2-73 composition comprises a crystalline form of A2-73 or A2-73 free base and is administered in an amount of about 50 mg once daily for a period of up to 11 weeks.
48. 46. The method of any one of claims 40-45, wherein the A2-73 composition comprises a crystalline form of A2-73 or A2-73 free base and is administered once daily in escalating doses starting at about 10 mg and ending at about 50 mg for a period of up to 11 weeks.
49. The method according to any one of claims 1 to 48, wherein the disease is Parkinson's disease or a prion disease.
50. 50. The method of any one of claims 11 to 49, wherein the first biological sample or the second biological sample each independently comprises a serum sample, a plasma sample, or a sample suitable for transcriptome analysis.
51. 1) a first container for containing a first biological sample; 2) a second container for containing a second biological sample; 3) a third container for storing reagents for sequencing or measuring gene expression; 4) a fourth container for storing a composition comprising a sigma-1 receptor agonist; and 5) Instructions for use in print or computer-readable media 23. A kit for medical use comprising:
52. The medical use, i) selecting a therapeutic agent for a subject; ii) assessing the efficacy of neurodegenerative therapeutics; iii) identifying subjects who respond to sigma-1 receptor agonist therapy; or iv) determining whether the subject has, is suspected of having, or is at increased risk for developing a disease selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction; 52. The kit of claim 51, comprising one or more of:
53. 53. The kit of claim 52, wherein the disease is Parkinson's disease or a prion disease.
54. 54. The kit of any one of claims 51 to 53, wherein the sigma-1 receptor agonist comprises ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, L-687,384, SA-4503, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts.
55. 55. The kit of any one of claims 51 to 54, wherein the composition comprises an oral composition comprising A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
56. 1. A sigma-1 receptor agonist for use as a medicament in the treatment of a disorder selected from Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, a disorder associated with myocardial contraction, or any combination thereof.
57. 1. A method of treating a neurodegenerative disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a sigma-1 receptor agonist, wherein the disorder is selected from the group consisting of Huntington's disease, amyotrophic lateral sclerosis, prion disease, diabetic cardiomyopathy, non-alcoholic fatty liver disease, coronavirus disease, a disorder associated with thermogenesis, a disorder associated with oxidative phosphorylation, a disorder associated with proteasome dysfunction, a disorder associated with ribosomal dysfunction, a disorder associated with retrograde endocannabinoid signaling, and a disorder associated with myocardial contraction.
58. 58. The use or method of claims 56-57, wherein the sigma-1 receptor agonist comprises ANAVEX 2-73 (A2-73), A2-73 free base, ANAVEX 19-144, ANAVEX 1-41, AV1066, ANAVEX 3-71, PRE-084, donepezil, fluvoxamine, amitriptyline, L-687,384, SA-4503, dextromethorphan, dimethyltryptamine, (+)-pentazocine, or any of their crystalline forms, enantiomers, and pharma- ceutically acceptable salts.
59. 58. The use or method of claims 56-57, wherein the sigma-1 receptor agonist comprises A2-73 free base, A2-73 amorphous form, A2-73 crystalline form I, A2-73 crystalline form II, A2-73 crystalline form III, the (-) A2-73 enantiomer, the (+) A2-73 enantiomer, or any combination thereof.
60. 58. The method of claim 57, wherein the therapeutically effective amount comprises A2-73 in an amount between 0.5 mg and 100 mg per day.
61. 58. The method of claim 57, wherein the therapeutically effective amount comprises A2-73 in an amount of 10 mg to 50 mg per day.
62. The method of any one of claims 1 to 48 and 57, wherein the disorder is Parkinson's disease and the therapeutically effective amount comprises A2-73 in an amount of 10 mg to 50 mg per day.
63. The method of any one of claims 1 to 48 and 57, wherein the disorder is a prion disease and the therapeutically effective amount comprises A2-73 in an amount of 0.5 mg to 100 mg per day.
64. The method of any one of claims 1 to 50 and 57, wherein the subject is a human subject or a non-human mammal.
